ICU SEASTAR MEDICAL HOLDING CORPORATION

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

DENVER, Oct. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit hosted by M-Vest on Wednesday, October 16, at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The fireside chat will be hosted by Maxim Group analyst Anthony Vendetti.

Registration for the M-Vest platform to access to the live and archived presentation webcast will be posted to section of the SeaStar Medical website.

About SeaStar Medical

SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contact:

LHA Investor Relations

Jody Cain

(310) 691-7100

# # #



EN
09/10/2024

Underlying

ICUSEASTAR MEDICAL HOLDING CORPORATION

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEASTAR MEDICAL HOLDING CORPORATION

 PRESS RELEASE
Free
ICU SEASTAR MEDICAL...

SeaStar Medical Reports Second Quarter 2025 Financial Results and Prov...

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolledThree new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Positive survival results reported from QUELIMMUNE SAVE Surveillance RegistryWebcast call today at 4:30 p.m. Eastern Time DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatm...

August 13, 2025 1 EN
 PRESS RELEASE
Free
ICU SEASTAR MEDICAL...

SeaStar Medical to Report Second Quarter Financial Results on August 1...

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025 DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, August 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, August 13, 2025, at 4:30 p.m...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ICU SEASTAR MEDICAL...

SeaStar Medical Announces $4.4 Million Registered Direct Offering Pric...

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules DENVER, July 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 4,960,544 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.887 per share of common stock (or...

July 31, 2025 1 EN
 PRESS RELEASE
Free
ICU SEASTAR MEDICAL...

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Ped...

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients DENVER, July 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the which is assessing the use of the in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT). Based on the data collected from the first 20 pediatric pati...

July 22, 2025 1 EN
 PRESS RELEASE
Free
ICU SEASTAR MEDICAL...

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillanc...

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry Highest Rated Children’s Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI HDE Surveillance Registry Data Captures Key Metrics for Future Analysis of QUELIMMUNE Performance DENVER, July 16, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company announced today that it has added a nationally-recognized, Texas-based children’s hospital to its growing customer base of QUELIMMUNE therapy users. The was approved by the U.S. Fo...

July 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch